SequelSEC

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL

Services-Commercial Physical & Biological Research · CIK 0001100682 · Fiscal year ends 1227

AnnualQuarterlyTTM
Revenue
$4.00B
Fiscal year ended 2026-06-27
Operating income
$90.14M
Fiscal year ended 2026-06-27
Free cash flow
Unavailable
Fiscal year ended 2026-06-27

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported revenue of $4.00B and net income of -$238.46M for the fiscal year ended 2026-06-27. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-27
Revenue$4.00B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$90.14M
Net income-$238.46M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$52.62M
Diluted EPSUnavailable
Selling, general & administrative$762.04M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-27
Cash & equivalents$192.02M
Total assets$7.53B
Current assets$1.53B
Total liabilities$4.64B
Current liabilities$1.13B
Total equity incl. NCI$2.85B
Temporary (mezzanine) equity$42.54M
Inventory$346.26M
Accounts receivable$711.76M
Goodwill$3.08B
Long-term debt$2.62B
Accounts payable$140.98M

Cash flow

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-27
Operating cash flow$582.15M
Capital expendituresUnavailable
Investing cash flow-$506.25M
Financing cash flow-$21.42M
Net change in cash$55.84M
Stock-based compensation$83.06M
Common dividends paidUnavailable
Common share repurchases$324.07M
Depreciation & amortization$297.88M

Derived

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-27
Free cash flowUnavailable
Gross marginUnavailable
Operating margin2.3%
FCF marginUnavailable
SBC / revenue2.1%
Current ratio1.35x
Revenue YoY growth-0.7%
Net margin-6.0%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equity0.92x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CRL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-18View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABSI BIAF BUDZ CBIH FOXO IBAC INCY IQV ISPC MEDP MXCT NRC

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.